featured
Six vs Twelve Months of Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Six Versus Twelve Months of Adjuvant Trastuzumab in Combination With Dose-Dense Chemotherapy for Women With HER2-Positive Breast Cancer: A Multicenter Randomized Study by the Hellenic Oncology Research Group (HORG)
Ann. Oncol 2015 May 01;[EPub Ahead of Print], D Mavroudis, E Saloustros, N Malamos, S Kakolyris, I Boukovinas, P Papakotoulas, N Kentepozidis, N Ziras, V GeorgouliasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.